ROVI Laboratorios Farmaceuticos Rovi, S.A.

72.61USD66.20 EUR · BME-2.00%Mkt Cap: 3.71B USDP/E: 16.23

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, B…

Institutional holders10 on file

Key Statistics

Company
Market Cap3.71B USD
Enterprise Value3.76B USD
Revenue (TTM)908.80M USD
Gross Profit529.41M USD
Net Income (TTM)154.04M USD
Revenue/Share17.77 USD
Last Price72.61 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.9K
CountryES
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINES0157261019
Valuation
P/E (Trailing)16.23
P/E (Forward)20.06
PEG1.26
EV/EBITDA17.53
EV/Revenue4.14
P/S4.08
P/B4.34
EPS (TTM)4.47 USD
EPS (Forward)3.61 USD
52W Range
58.2439% of range95.09
52W High95.09 USD
52W Low58.24 USD
Profitability
Gross Margin64.92%
Oper. Margin20.23%
EBITDA Margin23.61%
Profit Margin18.89%
ROE21.14%
ROA14.70%
ROIC20.35%
ROCE23.99%
Growth
Revenue Growth26.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF205.19M USD
CapEx (TTM)74.38M USD
FCF Margin11.72%
FCF Yield2.87%
Net Debt32.94M USD
Net Debt/EBITDA0.15
Net Debt/FCF0.31
Balance Sheet
Debt/Equity0.18
Current Ratio2.68
Quick Ratio1.50
Book Value/Sh16.72 USD
Cash/Share1.52 USD
Dividends
Fwd Div Rate1.05 USD
Trail. Div Rate0.00 USD
Div. Yield1.42%
5Y Avg Yield1.43%
Payout Ratio25.83%
Ex-Div DateJul 13, 2026
Pay Date—
Analyst Consensus
Rating2.2 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)82.26 USD
Upside (mean)+13.3%
Target Range73.49 USD – 97.62 USD
73.49+13.3% to mean97.62
# Analysts9
Ownership
Shares Out.51.14M
Float16.20M
Insiders68.20%
Institutions16.86%
Technical
SMA 5067.13 (+8.2%)
SMA 20072.17 (+0.6%)
Beta0.28
S&P 52W Chg12.00%
Avg Vol (30d)85.10K
Avg Vol (10d)161.54K
Technical Indicators
RSI (14)55.0
MACD2.2338
MACD Signal2.4299
MACD Hist.-0.1961
BB Upper80.28 USD
BB Middle72.26 USD
BB Lower64.24 USD
BB Width22.20%
ATR (14)1.729 USD
Vol Ratio (20d)0.72x

About Laboratorios Farmaceuticos Rovi (BME: ROVI)

›

Laboratorios Farmaceuticos Rovi (BME: ROVI) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 1,950 employees.

The shares were at 66.20 EUR on 19 November 2026, up 14.9% over 52 weeks. Its 52-week range is 53.10 EUR to 86.70 EUR: the price is 23.6% below the high and 24.7% above the low.

At a market capitalisation of 3.39B EUR, it trades at 16.2 times trailing earnings and 20.1 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 34% for ROVI. It pays a dividend yielding 1.42% (it pays out 26% of its earnings), against a median of 1.90% among the dividend payers in that peer group.

Laboratorios Farmaceuticos Rovi reports return on equity of 21.1%, an operating margin of 20.2% and revenue up 26.4% year over year.

Its debt exceeds its cash by 30.03M EUR, a debt-to-equity ratio of 0.18. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 75.00 EUR is 13.3% above the current price. The next earnings report is expected on 24 February 2027.